StockMirror — Stock Screener

SHILPAMED Q2 FY27 Results & Earnings Analysis

Sentiment: Great (Confidence: high)

Earnings Summary

Shilpa Medicare delivered record Q2 FY27 revenues of INR538 crores (up 35% YoY) and H1 revenues of INR1,007 crores (up 44% YoY), with highest ever EBITDA and PAT. All four business segments (API, Formulation, Biologics, CDMO) contributed to growth. Gross margins declined ~700 bps due to higher API sales mix and raw material cost inflation. Management is investing in peptide capacity, biosimilars, and complex formulations, with multiple launches and partner program commercializations expected in FY28 and beyond. ROCE improved to 13.3% (adjusted 18.3%). Management expressed confidence in continuing momentum, though specific guidance was not provided.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasized growth through multiple engines and new launches while also highlighting operating leverage, ROCE improvement, and focus on high gross margin businesses (peptides, oncology APIs, CDMO). They expect ROCE to improve as capacities fill.

About Shilpa Medicare Limited

Shilpa Medicare Limited (SHILPAMED) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More